Literature DB >> 28477700

Rituximab in anti-MAG neuropathy: More evidence for efficacy and more predictive factors.

Marinos C Dalakas1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28477700     DOI: 10.1016/j.jns.2017.04.016

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


× No keyword cloud information.
  3 in total

Review 1.  Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies.

Authors:  Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2018-01-15       Impact factor: 6.570

2.  Obinutuzumab, a potent anti-B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy.

Authors:  Goran Rakocevic; Ubaldo Martinez-Outschoorn; Marinos C Dalakas
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2018-04-05

Review 3.  Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies.

Authors:  Chiara Briani; Andrea Visentin
Journal:  Neurotherapeutics       Date:  2022-03-28       Impact factor: 6.088

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.